Talimogene Laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III-IV melanoma: a case series

Journal for Immunotherapy of Cancer
Lillian SunBrian Gastman

Abstract

Talimogene Laherparepvec (T-VEC) is an oncolytic virus approved as an intratumoral therapy for treating unresectable stage IIIB-IV metastatic melanoma. The mechanisms of action for T-VEC and checkpoint inhibitor are highly complementary. Recent studies have shown that combining checkpoint inhibitor therapy with T-VEC injection can lead to improved response rates for stage IIIB-IV melanoma patients. We reviewed 10 consecutive cases of stage IIIC to stage IVM1b melanoma patients that received T-VEC plus checkpoint inhibitor(s) therapy (pembrolizumab, ipilimumab/nivolumab, or nivolumab) treated between June 2016 and August 2017 at the Cleveland Clinic with a median follow-up of 7 months (range: 4 to 13 months). Responses of injected (on-target) and uninjected (off-target) lesions were evaluated according to RECIST 2.0. The overall response rate for on-target lesions was 90%, with 6 patients experiencing a complete response in injected lesions. Two patients had off-target lesions, which were completely resolved after treatment. Blood samples were tested for 3 complete responders and 2 partial responders. CD4:CD8 ratio and frequencies of circulating PD1+ CD4 and CD8 T cells were elevated in complete responders but not partial respon...Continue Reading

References

Mar 30, 2010·The Oncologist·David Moreno-RamirezAdoracion Nieto-Garcia
Aug 22, 2014·International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group·Roger Olofsson BaggeLo Hafström
May 28, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert H I AndtbackaRobert S Coffin
Nov 11, 2015·Cancer Discovery·Alissa Poh
Jan 1, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Frederick J Kohlhapp, Howard L Kaufman
Jun 15, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Igor PuzanovRobert H I Andtbacka
Jul 4, 2016·Cancer Immunology, Immunotherapy : CII·Christoph HoellerChristian U Blank
Feb 27, 2017·Cancer Immunology, Immunotherapy : CII·Reinhard DummerOlivier Michielin

❮ Previous
Next ❯

Citations

Apr 25, 2019·Integrative Cancer Therapies·Arthur E FrankelAndrew Y Koh
May 6, 2019·Current Treatment Options in Oncology·Ion G Motofei
Apr 9, 2020·Current Treatment Options in Oncology·Megan H TragerYvonne M Saenger
May 30, 2020·Cell Research·Yonina R Murciano-GoroffJedd D Wolchok
Aug 16, 2019·Therapeutic Advances in Vaccines and Immunotherapy·Brendon J Coventry
Feb 7, 2019·Frontiers in Immunology·Jan B BoscheinenPhilipp Schuster
Jun 20, 2020·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gregory V GoldmacherLawrence H Schwartz
Jul 1, 2020·Journal of Hematology & Oncology·Otto HemminkiAkseli Hemminki
Sep 24, 2020·Journal of the Endocrine Society·Zoe QuandtArabella Young
Oct 10, 2018·Frontiers in Immunology·Amanda Rosewell Shaw, Masataka Suzuki
Nov 10, 2020·Melanoma Research·Trevor S AndersonDevin B Lowe
Nov 2, 2020·Molecular Therapy : the Journal of the American Society of Gene Therapy·Liming ZhangYoujia Cao
Oct 24, 2020·Cancers·Lukasz KurykMariangela Garofalo
Dec 25, 2019·Current Opinion in Biotechnology·Erkko Ylösmäki, Vincenzo Cerullo
Feb 21, 2021·Journal for Immunotherapy of Cancer·Julia Maria ResslerChristoph Hoeller
Jan 28, 2021·Cell Biology International·Guang-Lin LeiPeng-Hui Yang
Mar 10, 2021·International Journal of Cancer. Journal International Du Cancer·Ibrahim Ragab EissaHideki Kasuya
Apr 9, 2021·Expert Review of Anticancer Therapy·Yizhen JinMei Liu
Apr 25, 2021·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Chen YangXiangmin Tong
Apr 28, 2021·Translational Research : the Journal of Laboratory and Clinical Medicine·Noraini Abd-Aziz, Chit Laa Poh
Jun 30, 2019·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R KnackstedtB Gastman
Jul 25, 2021·Journal of Experimental & Clinical Cancer Research : CR·Michele MaioUNKNOWN Siena Think Tank

❮ Previous
Next ❯

Methods Mentioned

BETA
density-gradient centrifugation

Clinical Trials Mentioned

NCT02307149

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Cancer Immunotherapy

Cancer immunotherapy is an important field of research that is looking at controlling cancer and tumor growth by activating the individuals own immune system. Recent studies have utilized chimeric antigen receptor t-cell therapy, immune checkpoint inhibitors and neoantigen vaccines. Discover the latest research on cancer immunotherapy here.

Related Papers

European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
Cindy FranklinDirk Schadendorf
Clinical Advances in Hematology & Oncology : H&O
Robert H I Andtbacka
© 2022 Meta ULC. All rights reserved